Theranostic vNAR-Based Immunoconjugates Achieve Selective Intracellular Cisplatin Delivery in Embedded 3D HER2-Positive Breast Cancer In Vitro Model
: By integrating tumor-restricted targeting and efficient intracellular drug delivery within a modular single-domain scaffold, vNAR R426 represents a next-generation theranostic platform capable of addressing intratumoral heterogeneity. This approach combines potent cytotoxic activity with immunofluorescence-based detection, thereby advancing the rational design of precision therapeutics for HER2-positive breast cancer.
Authors
- Mirna Burciaga-Flores (ORCID: https://orcid.org/0000-0002-9095-3563)
- Tanya A. Camacho-Villegas (ORCID: https://orcid.org/0000-0002-0540-0287)
- Pavel H. Lugo-Fabres (ORCID: https://orcid.org/0000-0001-8872-8335)
- Andrea P. Guevara (ORCID: https://orcid.org/0000-0002-7496-4772)
- Alejandro Manzanares-Guzmán (ORCID: https://orcid.org/0000-0002-2933-4720)
- Jessica A. Badillo-Mata
Institutions
- Universidad Autónoma de Baja California (MX)
- Secretaría de Salud de Jalisco (MX)
- Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (MX)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-04-17
- DOI
- https://doi.org/10.3390/ph19040633
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00